Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T17:33:19.467Z.
Calculation as of: 2026-10-06T17:33:19.467Z.
Quote observation: 2026-10-06T17:29:43.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b447d722f006e82d19b5d98ef6acffd249f934693947ae19b5e437b2b2585766
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$535.61M
EV/Sales Ratio
62.84x
TTM Avg
53.58x
3Y Avg
21.24x
5Y Avg
46.54x
Market Cap
$534.74M
EV/Sales Ratio
5.13x
TTM Avg
4.75x
3Y Avg
15.43x
5Y Avg
15.84x
Market Cap
$534.10M
EV/Sales Ratio
473.48x
TTM Avg
465.17x
3Y Avg
224.57x
5Y Avg
162.02x
Market Cap
$532.96M
EV/Sales Ratio
564.32x
TTM Avg
273.93x
3Y Avg
336.09x
5Y Avg
336.09x
Market Cap
$532.00M
EV/Sales Ratio
2.16x
TTM Avg
5.65x
3Y Avg
62.35x
5Y Avg
62.35x
Market Cap
$526.66M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | $536.14M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $535.61M | 62.84x | 53.58x | 21.24x | 46.54x |
| Delcath Systems, Inc. (DCTH)vs › | $534.74M | 5.13x | 4.75x | 15.43x | 15.84x |
| Shattuck Labs, Inc. (STTK)vs › | $534.10M | 473.48x | 465.17x | 224.57x | 162.02x |
| ProKidney Corp. (PROK)vs › | $532.96M | 564.32x | 273.93x | 336.09x | 336.09x |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $532.00M | 2.16x | 5.65x | 62.35x | 62.35x |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $526.66M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $523.67M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $518.71M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.76M | 29.85x | 14.16x | 5.32x | 4.09x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
